Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Takeda

My snoring is waking up my partner. Apart from a CPAP machine, what are the options?

Snoring happens when the muscles and tissues that surround the upper airway (at the back of the nose to the throat region) vibrate during sleep. Snoring can disturb your bed partner’s sleep, and it can be a symptom of the most common sleep-related breathing disorder, obstructive sleep apnoea.

The Conversation

For Highland Park man, why did a single shot of a very old cancer drug cost $38,398?

For Highland Park man, why did a single shot of a very old cancer drug cost $38,398?

What’s behind the $38,398 price tag for a single dose of the drug to treat prostate cancer? A mixture of unrelenting drug price increases and hospital system consolidation.

Chicago Sun-Times

It cost $38,398 for a single shot of a very old cancer drug

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It costs a few hundred dollars in the U.K. — so why are U.S. hospitals charging so much more to administer it?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

EU regulator recommends clearing Takeda's dengue vaccine

The European Medicines Agency is recommending that a dengue vaccine made by the Japanese pharmaceutical Takeda be authorized, in a move that could provide a new tool for millions worldwide against the potentially fatal disease

The Independent UK

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%. FY21 net profit declined 38.8% to ¥230.1 billion. Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%. Gastroenterology…

inkl

Read news from The Economist, FT, and more,
with one subscription

What's Going On With Novavax Stock Today?

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares are trading lower Tuesday. The stock fell to new 52-week lows early in the session, but has since recovered.

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

Shattuck Labs SL-9258 /Anti-PD(L)1 Shows Broadened Anti-Tumor Activity In CPI-Resistant Cancers

Shattuck Labs SL-9258 /Anti-PD(L)1 Shows Broadened Anti-Tumor Activity In CPI-Resistant Cancers

Shattuck Labs Inc (NASDAQ:STTK) announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from SL-9258 (TIGIT-Fc-LIGHT) and the Company's GADLEN platform. Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrates that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands…

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact,

1 2

People

Kathaleen McCormick

Taylor Glascock

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Gastroenterology

Places

408,310 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play